前言

一年一度的肿瘤界“奥斯卡”——2024年美国临床肿瘤学会（ASCO）年会将于当地时间5月31日-6月4日在美国芝加哥盛大召开。ASCO年会汇聚世界各地的肿瘤学专家、医生、研究人员，旨在分享最新的肿瘤学研究成果、讨论前沿诊疗技术，推动肿瘤学领域的进步。日前，ASCO在线公布了本届大会入选的摘要标题，其中有21项中国研究入选口头报告，27项中国研究入选快速口头报告，7项中国研究入选临床科学研讨会，让我们先睹为快！

口头报告

摘要号：2003

Efficacy and safety of the vebreltinib in patients with previously treated, secondary glioblastoma/IDH mutant glioblastoma with PTPRZ1-METFUsion GENe (FUGEN): A randomised, multicentre, open-label, phase II/III trial

伯瑞替尼治疗既往经治的继发性胶质母细胞瘤/携带PTPRZ1-METFUsion GENe（FUGEN）的IDH突变型胶质母细胞瘤患者的疗效和安全性：一项随机、多中心、开放标签、II/III期研究

讲者：保肇实 首都医科大学附属北京天坛医院

摘要号：2007

High-dose almonertinib in treatment-naïve EGFR-mutated NSCLC with CNS metastases: Efficacy and biomarker analysis.

高剂量阿美替尼用于CNS转移的初治EGFR突变NSCLC：疗效和生物标志物分析

讲者：范云 浙江省肿瘤医院

摘要号：2501

Claudin18.2-targeted chimeric antigen receptor T cell-therapy for patients with gastrointestinal cancers: Final results of CT041-CG4006 phase 1 trial.

Claudin18.2靶向嵌合抗原受体T细胞治疗胃肠道癌症患者：CT041-CG4006 I期试验的最终结果

讲者：齐长松 北京大学肿瘤医院

摘要号：2502

A potential best-in-class BCMA-CD19 bispecific CART with advanced safety by self-inhibiting IFNG signaling during CRS.

一种潜在的best-in-class BCMA-CD19双特异性CAR-T，通过在细胞因子释放综合征期间自我抑制IFNG信号传导而具有先进的安全性

讲者：Lei Xue

摘要号：2504

Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies.

抗CCR8单克隆抗体LM-108联合抗PD-1抗体治疗胃癌患者的有效性和安全性：I/II期研究结果

讲者：Chang Liu 北京大学肿瘤医院

摘要号：3008

Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.

KRAS p.G12C抑制剂(glecirasib，JAB-21822)联合SHP2抑制剂(JAB-3312)治疗KRAS G12C突变实体瘤患者的最新安全性和有效性数据

讲者：赵军 北京大学肿瘤医院

摘要号：3505

Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study.

高度微卫星不稳定/错配修复缺陷型结直肠癌患者接受IBI310(抗CTLA-4抗体)联合信迪利单抗(抗PD-1抗体)新辅助治疗：来自一项随机、开放标记、Ib期研究的结果

讲者：徐瑞华 中山大学肿瘤防治中心

摘要号：LBA6000

Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.

卡瑞利珠单抗辅助治疗高危局部晚期鼻咽癌(DIPPER)：一项多中心、开放标签、III期随机对照试验

讲者：刘需 中山大学肿瘤防治中心

摘要号：6001

Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial.

替雷利珠单抗对比安慰剂联合诱导化疗序贯同步放化疗，继以替雷利珠单抗或安慰剂辅助治疗局部晚期鼻咽癌：一项多中心、随机、安慰剂对照、双盲、III期试验的期中分析

讲者：陈秋燕 中山大学肿瘤防治中心

摘要号：6002

Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial.

Endostar联合同步放化疗对比单纯同步放化疗应用于局部晚期咽癌(LA-NPC)的疗效：一项III期、前瞻性、随机对照、多中心临床试验

讲者：康敏 广西医科大学第一附属医院

摘要号：6505

Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

一种新型CD3xCD19 IgG4双特异性抗体CN201用于复发性或难治性B细胞急性淋巴细胞白血病成人患者的I期研究

讲者：王迎 中国医学科学院血液病医院(中国医学科学院血液学研究所)

摘要号：7002

CLAMP: A phase II prospective study of camrelizumab combined with pegaspargase, etoposide, and high-dose methotrexate in patients with natural killer (NK)/T-cell lymphoma.

CLAMP研究：一项卡瑞利珠单抗联合培门冬酶、依托泊苷和大剂量甲氨蝶呤治疗自然杀伤(NK)/T细胞淋巴瘤患者的II期前瞻性研究

讲者：刘涛 华中科技大学同济医学院附属协和医院

摘要号：LBA7003

Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study.

西达本胺联合R-CHOP治疗MYC和BCL2双表达的未经治疗的弥漫性大B细胞淋巴瘤：III期DEB研究的期中分析结果

讲者：赵维莅 上海交通大学医学院附属瑞金医院

摘要号：8004

Adjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): A randomized phase 3 trial.

可切除EGFR突变II-IIIA期NSCLC接受12个月或6个月的埃克替尼辅助治疗对比辅助化疗后观察：一项随机III期试验(ICTAN，GASTO1002)

讲者：王思愚 中山大学肿瘤防治中心

摘要号：8008

A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091).

一项II期随机试验评估新辅助化疗联合纳武利尤单抗和同步放化疗后巩固性纳武利尤单抗治疗局部晚期NSCLC的疗效(GASTO-1091)

讲者：刘慧 中山大学肿瘤防治中心

摘要号：8009

Taiwan national lung cancer early detection program for heavy smokers and non-smokers with family history of lung cancer.

台湾地区对于重度吸烟以及有肺癌家族史的非吸烟人群肺癌早期检测计划

讲者：Pan-Chyr Yang 台湾大学医学院

摘要号：8502

Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study

II期OptiTROP-Lung01研究：Sacituzumab tirumotecan(SKB264/MK-2870)联合KL-A167(抗PD-L1)作为中晚期NSCLC患者的一线治疗

讲者：方文峰 中山大学肿瘤防治中心

摘要号：8508

Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.

Ivonescimab联合化疗治疗接受EGFR-TKI治疗进展的EGFR突变非鳞状NSCLC患者(HARMONi-A)：一项随机、双盲、多中心、III期试验

讲者：张力 中山大学肿瘤防治中心

摘要号：11502

Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma

olverembatinib(HQP1351)在酪氨酸激酶抑制剂(TKI)耐药的琥珀酸脱氢酶(SDH)缺陷的胃肠道间质瘤(GIST)和副神经节瘤患者中的最新疗效结果

讲者：邱海波 中山大学肿瘤防治中心

摘要号：11505

Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patients with advanced undifferentiated pleomorphic sarcoma (UPS), synovial sarcoma (SS), myxoid liposarcoma (MLPS) and de-differentiated liposarcoma (DDLPS): A single-arm phase 2 trial

信迪利单抗、阿霉素和异环磷酰胺(AI)作为晚期未分化多形性肉瘤(UPS)、滑膜肉瘤(SS)、粘液样脂肪肉瘤(MLPS)和去分化脂肪肉瘤(DDLPS)患者一线治疗：单臂2期研究

讲者：罗志国 复旦大学附属肿瘤医院

摘要号：11507

ARTEMIS-002: Phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcom

ARTEMIS-002：HS-20093治疗复发或难治性骨肉瘤患者的II期研究

讲者：谢璐 北京大学人民医院

Rapid Oral Abstract Session

摘要号：1020

ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC).

ACE-Breast-02：新型抗HER2抗体偶联药物(ADC)ARX788对比拉帕替尼联合卡培他滨治疗HER2+晚期乳腺癌(ABC)的关键性II/III期试验

讲者：胡夕春 复旦大学附属肿瘤医院

摘要号：2518

Phase I study of GUCY2C CAR-T therapy IM96 in patients with metastatic colorectal cancer.

GUCY2C CAR-T疗法IM96应用于转移性结直肠癌患者中的I期研究

讲者：齐长松 北京大学肿瘤医院

摘要号：2519

Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study.

IBI389，一种抗CLDN18.2/CD3双特异性抗体，在实体瘤、胃或胃食管肿瘤患者中的安全性和初步疗效结果：一项I期剂量递增和扩展研究

讲者：Li Zheng 四川大学华西医院

摘要号：3012

Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors.

I/II期MHB088C研究结果：新型B7H3 ADC，结合强效DNA拓扑异构酶I抑制剂治疗复发或转移性实体瘤

讲者：沈琳 北京大学肿瘤医院

摘要号：3013

9MW2821, a nectin-4 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1/2a study.

9MW2821，一种连接蛋白-4抗体偶联药物(ADC)，用于晚期实体瘤患者：I/IIa期研究结果

讲者：张剑 复旦大学附属肿瘤医院

摘要号：LBA3511

Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, phase 3 trial.

全程新辅助治疗联合长程放疗对比同步放化疗应用于高危局部晚期直肠癌(TNTCRT)：一项多中心、随机、开放标签的III期试验

讲者：Xin Wang

摘要号：3514

Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion.

通过腹膜内或静脉输注对既往接受治疗的实体瘤患者进行缺氧反应性CEA CAR-T细胞治疗的I期试验

讲者：Hangyu Zhang 浙江大学医学院附属第一医院

摘要号：3516

Three-year disease-free survival after transanal vs. laparoscopic total mesorectal excision for rectal cancer (TaLaR): A randomized clinical trial.

经肛门切除对比腹腔镜直肠全系膜切除术后，直肠癌患者的三年无病生存率(TaLaR)：一项随机临床试验。

讲者：康亮 中山大学附属第六医院

摘要号：4012

Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer who failed immunochemotherapy: A multicenter, double-blind, randomized trial.

卡度尼利单抗联合pulocimab和紫杉醇作为免疫化疗失败的晚期胃或胃食管交界处(G/GEJ)癌症患者二线治疗的疗效和安全性：一项多中心、双盲、随机试验

讲者：张小田 北京大学肿瘤医院

摘要号：4019

Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC).

C-CAR031，一种GPC3特异性TGFβRIIDN的自体armored-CAR-T，应用于晚期肝细胞癌(HCC)患者的I期研究

讲者：章琦 浙江大学医学院附属第一医院

摘要号：4511

Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: A single-arm, open-label, phase 2 trial.

卡瑞利珠单抗联合阿帕替尼治疗既往经治的晚期肾上腺皮质癌：一项单臂、开放标签、II期试验

讲者：卫治功 四川大学华西医院

摘要号：5512

Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial.

信迪利单抗联合紫杉醇和顺铂作为局部晚期宫颈癌新辅助治疗的有效性和安全性：一项II期研究

讲者：刘继红 中山大学肿瘤防治中心

摘要号：5514

Nimotuzumab plus concurrent chemoradiotherapy for locally advanced cervical squamous cell carcinoma: The randomized, phase 3 CC3 study.

尼妥珠单抗联合同步放化疗治疗局部晚期宫颈鳞状细胞癌：随机、III期CC3研究

讲者：王俊杰 北京大学第三医院

摘要号：LBA5516

A phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer (SCORES).

suvemcitug联合化疗治疗铂类耐药卵巢癌的随机、双盲、安慰剂对照III期研究(SCORES)

讲者：袁光文 中国医学科学院肿瘤医院

摘要号：5520

Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A final overall survival analysis of a multicenter, open-label, randomized, phase 3 trial.

对铂敏感的复发性卵巢癌患者进行二次减瘤术后序贯化疗与单纯化疗的比较：一项多中心、开放标签、随机、III期试验(SOC-1)的最终总生存期分析

讲者：臧荣余 复旦大学附属中山医院

摘要号：6013

Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors.

pucotenlimab联合表皮生长因子受体-抗体药物偶联物(EGFR-ADC)MRG003治疗EGFR阳性实体肿瘤患者的I/II期研究初步结果

讲者：阮丹云 中山大学肿瘤防治中心

摘要号：LBA6018

Covalent FAPI PET enables accurate management of medullary thyroid carcinoma: a prospective single-arm comparative clinical trial.

共价结合的FAPI PET可精准治疗髓样甲状腺癌：一项前瞻性单臂比较性临床试验

讲者：孔梓任 中国医学科学院肿瘤医院

摘要号：6510

Latest results of a phase 2 study of IMM01 combined with azacitidine (AZA) as the first-line treatment in adults with higher risk myelodysplastic syndromes (MDS).

IMM01联合阿扎胞苷(AZA)作为高危骨髓增生异常综合征(MDS)成人患者一线治疗的II期研究的最新结果

讲者：杨威 中国医科大学附属盛京医院

摘要号：6515

Safety and efficacy of CD7-CAR-T cell in patients with relapsed/refractory T-lymphoblastic leukemia/lymphoma: Phase I dose-escalation/dose-expansion study.

CD7 CAR-T细胞治疗复发/难治性T淋巴母细胞白血病/淋巴瘤患者的安全性和有效性：I期剂量递增/剂量扩展研究

讲者：胡利娟 北京大学人民医院

摘要号：7017

Timdarpacept (IMM01) in combination with tislelizumab in prior anti-PD-1 failed classical Hodgkin lymphoma: An open label, multicenter, phase II study (IMM01-04) evaluating safety as well as preliminary anti-tumor activity.

Timdarpacept(IMM01)联合替雷利珠单抗治疗既往抗PD-1失败的经典霍奇金淋巴瘤：一项评估安全性以及初步抗肿瘤活性的开放标签、多中心、II期研究(IMM01-04)

讲者：王振玖

摘要号：7511

OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed/refractory multiple myeloma: Long term follow-up results of phase 1 study (POLARIS).

OriCAR-017是一种靶向GPRC5D的新型CAR-T，用于复发/难治性多发性骨髓瘤患者：I期研究(POLARIS)的长期随访结果

讲者：付珊 浙江大学医学院附属第一医院

摘要号：8014

Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer.

阿得贝利单抗联合化疗和序贯胸部放疗作为广泛期小细胞肺癌的一线治疗的总生存期

讲者：陈大卫 山东第一医科大学附属肿瘤医院

摘要号：8513

A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study

舒沃替尼治疗含铂化疗失败的EGFR 20号外显子插入突变非小细胞肺癌：一项国际多中心注册临床研究，WU-KONG1研究的初步分析结果

讲者：杨志新 中国国立台湾大学肿瘤中心医院

摘要号：8520

Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study.

taletrectinib治疗晚期或转移性ROS1阳性NSCLC患者的疗效和安全性：II期TRUST-I研究

讲者：李玮 同济大学附属上海市肺科医院

摘要号：11515

A phase II study of anlotinib and an anti-PDL1 antibody in patients with alveolar soft part sarcoma: Results of expansion cohorts

安罗替尼联合抗PD-L1抗体治疗肺泡软组织肉瘤患者的II期研究：扩展队列结果

讲者：刘佳勇 北京大学肿瘤医院

摘要号：11518

Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST)

NB003(一种广谱KIT/PDGFRα抑制剂)在晚期胃肠道间质瘤(GIST)患者中的I期研究

讲者：李健 北京大学肿瘤医院

摘要号：12013

Effect of nurse-led multi-disciplinary treatment on patients with head and neck tumors: A randomized controlled trial

护士主导的多学科治疗对头颈肿瘤患者的影响：一项随机对照试验

讲者：王晶晶 四川大学华西医院

Clinical Science Symposium

摘要号：104

Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study.

Sacituzumab tirumotecan(SKB264/MK-2870)用于既往经治的局部复发或转移性三阴性乳腺癌(TNBC)患者：III期OptiTROP-Breast01研究结果

讲者：樊英 中国医学科学院肿瘤医院

摘要号：4009

Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma: A multicenter, single-arm, phase II trial (RCTS).

维迪西妥单抗(RC48)联合替雷利珠单抗和S-1作为HER2过表达的晚期胃或胃食管交界处腺癌患者一线治疗的疗效：一项多中心、单臂、II期试验(RCTS)

讲者：刘联 山东大学齐鲁医院

摘要号：4010

A novel and uniquely designed bispecific antibody (LBL-024) against PD-L1 and 4-1BB in patients with advanced malignant tumors and neuroendocrine carcinoma: A report of safety and robust efficacy of LBL-024 monotherapy in phase I/II, first-in-human, open-label, multicenter, dose escalation/expansion study.

一种新型独特设计的针对晚期恶性肿瘤和神经内分泌癌的靶向PD-L1和4-1BB的双特异性抗体(LBL-024)：LBL-024单药治疗的开放标签、多中心、剂量递增/扩展、首次人体试验的安全性和疗效研究报告

讲者：张攀攀 北京大学肿瘤医院

摘要号：4011

Safety and efficacy of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: Preliminary results from a phase 1 study.

抗CLDN18.2/CD3双特异性抗体IBI389治疗晚期胰腺导管腺癌患者的安全性和有效性：I期研究的初步结果。

讲者：郝继辉 天津医科大学肿瘤医院

摘要号：5509

A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort.

TORC1/2抑制剂onatasertib联合特瑞普利单抗治疗晚期实体瘤患者的I/II期研究：宫颈癌队列

讲者：Hui Xie 德琪医药

摘要号：6011

Neoadjuvant sintilimab and platinum-doublet chemotherapy followed by transoral robotic surgery for HPV-associated resectable oropharyngeal cancer: Single-arm, phase II trial.

信迪利单抗联合含铂双药化疗新辅助治疗经口机器人手术治疗的HPV相关可切除口咽癌：单臂II期试验

讲者：宋明 中山大学肿瘤防治中心

摘要号：LBA8509

KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.

III期KRYSTAL-12研究：adagrasib对比多西他赛治疗经治的KRAS G12C突变晚期/转移性NSCLC患者

讲者：莫树锦 香港中文大学

备注：

排名不分先后，按照摘要号进行排序

如有遗漏或任何问题，请给我们留言~

编辑：Jiangtao Xin

审校：Faline

(本网站所有内容，凡注明来源为“医脉通”，版权均归医脉通所有，未经授权，任何媒体、网站或个人不得转载，否则将追究法律责任，授权转载时须注明“来源：医脉通”。本网注明来源为其他媒体的内容为转载，转载仅作观点分享，版权归原作者所有，如有侵犯版权，请及时联系我们。)